ArticleNuclear medicine and molecular imaging2014
Expression patterns of glucose transporter-1 gene and thyroid specific genes in human papillary thyroid carcinoma.
Article in Nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- [Molecular imaging and biology · 2023Trial
- Glucose Metabolic Reprogramming in Thyroid Cancer: Underlying Molecular Mechanisms and Links to Progression and Treatment.Current medical science · 2026Review
- Reflections on the 2024 KTA Guideline and the Role of Radioiodine Therapy in Differentiated Thyroid Cancer.Nuclear medicine and molecular imaging · 2025Article
- Computational Analysis Suggests That AsnGTT 3'-tRNA-Derived Fragments Are Potential Biomarkers in Papillary Thyroid Carcinoma.International journal of molecular sciences · 2024Article
- An age-and sex-matched postoperative therapy should be required in thyroid papillary carcinoma.Frontiers in endocrinology · 2024Article
- Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer.Surgery · 2024Article
- Reprogramming of Cellular Metabolism and Its Therapeutic Applications in Thyroid Cancer.Metabolites · 2022Review
- Sinomenine Hydrochloride Promotes TSHR-Dependent Redifferentiation in Papillary Thyroid Cancer.International journal of molecular sciences · 2022Article
- Review
- Metabolic Reprogramming of Thyroid Cancer Cells and Crosstalk in Their Microenvironment.Frontiers in oncology · 2021Review
- Comprehensive gene expression analysis for exploring the association between glucose metabolism and differentiation of thyroid cancer.BMC cancer · 2019Article
- Metabolic reprogramming and its clinical application in thyroid cancer.Oncology letters · 2019Review
- Iodine promotes thyroid cancer development via SPANXA1 through the PI3K/AKT signalling pathway.Oncology letters · 2019Article
- Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer.Oncotarget · 2019Article
- MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells HarboringMolecular therapy oncolytics · 2019Article
- FDG PET/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma.PloS one · 2019Article
- Differentiated thyroid cancer theranostics: radioiodine and beyond.The British journal of radiology · 2018Review
- Sodium Iodide Symporter (NIS) in the Management of Patients with Thyroid Carcinoma.Nuclear medicine and molecular imaging · 2018Article
- mRNA Expression of SLC5A5 and SLC2A Family Genes in Papillary Thyroid Cancer: An Analysis of The Cancer Genome Atlas.Yonsei medical journal · 2018Article
- The Predictive Values of Lesion Size, F-18 FDG Avidity and I-131 Avidity for the Clinical Outcome of I-131 Treatment in Patients with Metastatic Differentiated Thyroid Carcinoma Only in the Lung.Nuclear medicine and molecular imaging · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe expression of glucose transporter-1 (Glut-1) gene and those of major thyroid-specific genes were examined in papillary carcinoma tissues, and the expressions of these genes were compared with cancer differentiation grades. MATERIALS AND
methodsTwenty-four human papillary carcinoma tissues were included in this study. The expressions of Glut-1- and thyroid-specific genes [sodium/iodide symporter (NIS), thyroid peroxidase, thyroglobulin, TSH receptor and pendrin] were analyzed by RT-PCR. Expression levels were expressed as ratios versus the expression of beta-actin. Pathologic differentiation of papillary carcinoma was classified into a relatively well-differentiated group (n = 13) and relatively less differentiated group (n = 11).
resultsGlut-1 gene expression was significantly higher in the less differentiated group (0.66 ± 0.04) than in the well-differentiated group (0.59 ± 0.07). The expression levels of the NIS, PD and TG genes were significantly higher in the well-differentiated group (NIS: 0.67 ± 0.20, PD: 0.65 ± 0.21, TG: 0.74 ± 0.16) than in the less differentiated group (NIS: 0.36 ± 0.05, PD: 0.49 ± 0.08, TG: 0.60 ± 0.11), respectively. A significant negative correlation was found between Glut-1 and NIS expression, and positive correlations were found between NIS and TG, and between NIS and PD.
conclusionThe NIS, PD and TG genes were highly expressed in well-differentiated thyroid carcinomas, whereas the Glut-1 gene was highly expressed in less differentiated thyroid carcinomas. These findings provide a molecular rationale for the management of papillary carcinoma, especially in the selection of FDG PET or radioiodine whole-body scan and I-131-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.